Cargando…

POSA225 Comparing the US Drug Development, Pricing, Access, and Reimbursement Strategies for COVID-19 Vaccines as a Potential Model for Novel Oncology Therapies

Detalles Bibliográficos
Autores principales:	Lee, Y, Lee, K, Park, H, Neese, M, Khan, ZM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769589/ http://dx.doi.org/10.1016/j.jval.2021.11.698

Ejemplares similares

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016)

Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
por: Rachamin, Yael, et al.
Publicado: (2021)

Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
Publicado: (2022)

Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

Donde el polvo se posa /
por: Bespalova, Marina, 1970-
Publicado: (1994)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction
por: Kim, Sungju, et al.
Publicado: (2020)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

POSA279 The Impact of the COVID-19 Pandemic on the MHRA’s Early Access to Medicines Scheme
por: Ruane, P, et al.
Publicado: (2022)

From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
por: Panteli, Dimitra, et al.
Publicado: (2015)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

The timelines for the price and reimbursement authorization in Italy 2018–2020
por: Gallo, Valentina, et al.
Publicado: (2022)

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World
por: Goldstein, Daniel A., et al.
Publicado: (2016)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US
por: Horný, Michal, et al.
Publicado: (2021)

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
por: Drummond, Michael, et al.
Publicado: (2010)

Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)

POSA: Perl Objects for DNA Sequencing Data Analysis
por: Aerts, Jan A, et al.
Publicado: (2004)

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
por: Lee, SungKyung, et al.
Publicado: (2023)

Characterization of Posa and Posa-like virus genomes in fecal samples from humans, pigs, rats, and bats collected from a single location in Vietnam
por: Oude Munnink, Bas B., et al.
Publicado: (2017)

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France
por: Squara, Pierre-Alexandre, et al.
Publicado: (2022)

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency
por: Gandjour, Afschin
Publicado: (2020)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
por: Atikeler, Enver Kagan, et al.
Publicado: (2016)

Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?
por: Tamura, Makoto, et al.
Publicado: (2018)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

Transparency, Accessibility, and Variability of US Hospital Price Data
por: Haque, Waqas, et al.
Publicado: (2021)

POSA394 Mortality Curves Analysis of COVID-19 Hospitalizations in Oncologic Patients of a Private Health Care Plan in Brazil
por: Reis Neto, JP, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mgi2h02li7p08g5hu5rdvl3inq